National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources
skip sub-navigation, go to content.
Cancer Biomarkers Research Group

Funding Opportunities

This is a listing of Requests for Applications (RFA), Program Announcements (PA), and Notices specific to the group's key programs.

Requests For Applications (RFAs)


Tumor Stem Cells in Cancer Biology, Prevention, and Therapy (R01) >>> Learn more
RFA Number:RFA-CA-08-019
Release Date:February 22, 2008
Letter of Intent Date:April 12, 2008
Application Receipt Date:May 12, 2008
Expiration Date:May 13, 2008

Tumor Stem Cells in Cancer Biology, Prevention, and Therapy (P01) >>> Learn more
RFA Number:RFA-CA-08-020
Release Date:March 26, 2008
Letter of Intent Date:June 10, 2008
Application Receipt Date:July 10, 2008
Expiration Date:July 11, 2008

Program Announcements


Mitochondria in Cancer Epidemiology, Detection, Diagnosis and Prognosis (R01) >>> Learn more
PA Number:PA-08-143
Release Date:April 11, 2008
Application Receipt Date:Standard dates apply
Expiration Date:May 8, 2011

Mitochondria in Cancer Epidemiology, Detection, Diagnosis and Prognosis (R21) >>> Learn more
PA Number:PA-08-144
Release Date:April 11, 2008
Application Receipt Date:Standard dates apply
Expiration Date:May 8, 2011

Application of Metabolomics for Translational and Biological Research (R01) >>> Learn more
PA Number:PA-07-301
Release Date:January 17, 2007
Application Receipt Date: Standard dates apply
Expiration Date:January 3, 2010

Application of Metabolomics for Translational and Biological Research (R21) >>> Learn more
PA Number:PA-07-302
Release Date:January 17, 2007
Application Receipt Date: Standard dates apply
Expiration Date:January 3, 2010

Biomarkers of Infection-Associated Cancers (R01) >>> Learn more
PA Number:PA-08-156
Release Date:April 22, 2008
Application Receipt Date:Standard dates apply
Expiration Date:May 8, 2011

Clinical Cancer Therapy and Prevention Research (R01) >>> Learn more
PA Number:PA-07-356
Release Date:April 16, 2007
Application Receipt Date:Standard dates apply
Expiration Date:May 8, 2010

Biomarkers of Infection-Associated Cancers (R21) >>> Learn more
PA Number:PA-08-157
Release Date:April 22, 2008
Application Receipt Date:Standard dates apply
Expiration Date:May 8, 2011

Exfoliated Cells and Circulating DNA in Cancer Detection and Diagnosis (R21) >>> Learn more
PA Number:PA-06-499
Release Date:July 28, 2006
Application Receipt Date:Standard dates apply
Expiration Date:July 2, 2009

Cancer Prevention Research Small Grant Program (R03) >>> Learn more
PA Number:PAR-08-055
Release Dates:December 17, 2007
Application Receipt Dates:March 19, 2008; July 18, 2008; December 19, 2008; March 20, 2009; July 17, 2009; December 18, 2009; March 19, 2010; July 19, 2010; December 09, 2010
Expiration Date:December 10, 2010

Exploratory Studies in Cancer Detection, Diagnosis and Prognosis (R21) >>> Learn more
PA Number:PA-06-299
Release Dates:March 30, 2006
Application Receipt Date:Standard dates apply
Expiration Date:November 2, 2008 (now January 8, 2008 per NOT-OD-07-093)

Clinical Correlative Studies to Multi-Institutional Prevention and Treatment Trials (R21) >>> Learn more
PA Number:PA-06-296
Release Dates:March 29, 2006
Application Receipt Date:Standard dates apply
Expiration Date:March 2, 2008 (now May 8, 2008 per NOT-OD-07-093)

Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R21) >>> Learn more
PA Number:PA-06-295
Release DatesMarch 29, 2006
Application Receipt Date:Standard dates apply
Expiration Date:July 2, 2008

Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R21) >>> Learn more
PA Number:PA-06-303
Release Dates:March 31, 2006
Application Receipt Date:Standard dates apply
Expiration Date:July 2, 2008 (now September 8, 2008 per NOT-OD-07-093)

Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R21) >>> Learn more
PA Number:PA-06-303
Release Dates:March 31, 2006
Application Receipt Date:Standard dates apply
Expiration Date:July 2, 2008 (now September 8, 2008 per NOT-OD-07-093)

Pilot Studies in Pancreatic Cancer (R03) >>> Learn more
PA Number:PA-06-314
Release Dates:April 4, 2006
Application Receipt Date:Standard dates apply
Expiration Date:July 2, 2008 (now September 8, 2008 per NOT-OD-07-093)

NIH Support for Conferences and Scientific Meetings (R13/U13) >>> Learn more
PA Number:PA-06-041
Release Dates:October 26, 2005
Application Receipt Date:Standard dates apply
Expiration Date:September 2, 2008 (now September 8, 2008 per NOT-OD-07-093)

Back to TopBack to Top

Notices


NCI early Detection Research Network (EDRN) Program for Rapid, Independent Diagnostic Evaluation (PRIDE) for Cancer Biomarkers >>> Learn More
Notice Number:NOT-CA-08-023
Release Date:June 11, 2008

Back to TopBack to Top

IMAT Request for Applications


The Innovative Molecular Analysis Technologies (IMAT) Program, which is aimed at the development and integration of novel and emerging technologies in the support of cancer research, diagnosis, and treatment, now encompasses an array of 12 closely related Funding Opportunity Announcements (FOAs). Each FOA is segregated based on program and type of funding mechanism. The IMAT Program comprises the following three related thematic components which are described below and at the IMAT website in further depth. To learn more about IMAT Funding opportunities (R21, R33, SBIR and STTR applications) please visit http://imat.cancer.gov/funding/.

Innovative Technologies for the Molecular Analysis of Cancer
IMAT funding opportunities are designed to encourage applications from individuals and groups interested in developing novel technologies suitable for the molecular analysis of cancers and their host environment in support of basic, clinical, and epidemiological research.

Applications of Emerging Technologies for Cancer Research
Emerging Technologies funding opportunities are intended to support projects to evaluate the usefulness of emerging technologies in appropriate biological contexts in order to assess reproducibility and produce preliminary data toward a biological or clinical question.

Innovations in Cancer Cell Preparations.
Sample preparation methods and technologies may be developed for sample collection, processing, isolation, storage, purification, preservation, and, in the case of stored tissues, reversal of adverse events resulting from storage and preservation.

Back to TopBack to Top

EDRN Associate Membership Program


Applications are also accepted for becoming an Associate Member of NCI’s Early Detection Research Network. For details visit the EDRN Associate Membership Program.

Back to TopBack to Top